Compare Organon & Co. Common Stock (OGN) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Simon Property Group Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Simon Property Group Inc trades at $200.17 (market cap $64.92B). The key difference: Simon Property Group Inc is far larger — about 17.9× Organon & Co. Common Stock's market cap, and Simon Property Group Inc pays the higher dividend (4.44%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Simon Property Group Inc for 100 Days on average.
| OGN | SPG | |
|---|---|---|
Market Cap | $3.62B | $64.92B |
Volume | 2,892,999 | 1,919,136 |
Sector | Health | Real Estate |
52-Week High | $13.81 | $236.70 |
52-Week Low | $5.70 | $173.35 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $11.04B | $93.37B |
Dividend Yield | 0.58% | 4.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SPG trades at $198.70, down 1.35% with bearish technical signals from moving averages and ADX indicators. The REIT maintains strong fundamentals with Q4 2025 EPS beating expectations at $9.35 versus $1.90, though Q2 2026 missed at $1.49 versus $1.64. Recent news highlights strong leasing demand and a new $800 million debt issuance, while directors made small stock purchases in late September 2026.
SPG presents a mixed outlook with robust profitability metrics like 66.57% net margin and 135.7% ROE offset by negative net cash flow and high debt levels. The consensus price target of $218.45 suggests 10% upside potential, but rising bond yields and $2B in 2024 debt maturities pose headwinds for the retail REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
